Wiadomości Eulerpool Alligator Bioscience

Eulerpool-AFX Alligator Bioscience

Alligator Bioscience Wiadomości o akcjach

Alligator Bioscience jest obserwowany przez wielu dziennikarzy i inwestorów na całym świecie. Najnowsze wiadomości Alligator Bioscience przedstawiamy tutaj.

• 11 lipca ·

  Yahoo
  Alligator Bioscience AB Reports Financial Results for H1 2024 and Q2 2024 and Provides a Business Update
• 26 czerwca ·

  Yahoo
  Alligator Bioscience Announces Substantial Overall Survival Benefit and Unprecedented Duration of Response in the 18-Month Analysis from Mitazalimab OPTIMIZE-1 Phase 2 Study in 1st Line Pancreatic Cancer
• 25 czerwca ·

  Yahoo
  Alligator Bioscience Announces Financing of Up to SEK 80 Million Extending Cash Runway to Q1 2025
• 3 czerwca ·

  Yahoo
  Alligator Bioscience's Phase 2 mitazalimab Pancreatic Cancer Data Published in The Lancet Oncology
• 23 maja ·

  Yahoo
  Alligator Bioscience To Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting
• 1 kwietnia ·

  Yahoo
  Alligator Bioscience Announces Completion of 600 mg Dose Cohort for ATOR-1017, Dose-escalation and Enrollment for 900 mg dose Cohort Commences
• 23 marca ·

  Yahoo
  Alligator Bioscience Announces mitazalimab OPTIMIZE-1 Trial Update: Successful Completion of Phase Ib, Phase II enrolling at 900 µg/kg
• 11 lutego ·

  Yahoo
  Alligator Bioscience AB: Year End report January-December 2021
• 19 stycznia ·

  Yahoo
  Alligator Bioscience Announces Commencement of a Sponsored Research Agreement with the University of Pennsylvania Led by Dr. Gregory Beatty
• 18 stycznia ·

  Yahoo
  Alligator Bioscience Announces OPTIMIZE-1 Trial Update: Cohort Fully Dosed with No Adverse Effects Reported